Better Health, Brighter Future
Independent Medical Education Grants
Takeda and its Alliance partners are committed to supporting high-quality, un-biased, evidence-based independent medical education for healthcare professionals, teams, patients, payers and systems designed to:
- Improve knowledge, enhance skills, and support behavior change
- Close clinical and practice gaps
- Improve the quality and delivery of patient care
- Enable patients to take an active role in their healthcare
Independent Medical Education is defined as education that is evidence-based, fair-balanced, unbiased, planned and implemented independent of industry influence, free of bias and not influenced by Takeda or its Alliance partners.
Educational Areas of Interest
Below are areas of interest for independent medical education support by US Medical Affairs. If you have questions about an area not listed, please contact [email protected]
Gastroenterology
- Improving recognition and differential diagnosis of IBD earlier in the disease course
- Identifying sub-optimal response to conventional IBD therapy and making timely, evidence-based treatment changes to enable patients to achieve and maintain remission
- Recognizing and addressing care disparities and barriers to equitable care of patients with IBD
- Reviewing available and emerging therapies, and their place in the treatment landscape
- Determining individualized treatment selection and sequencing to prevent disease progression and to manage IBD long-term
- Using risk stratification, clinical factors, and patient factors to make evidence-based treatment decisions
- Providing culturally competent care that facilitates shared decision-making and encourages alignment of disease perception and treatment goals between patients and HCPs
- Exploring EoE pathophysiology, disease course and disease severity
- Applying current guidelines for the diagnosis and classification of EoE to reduce diagnostic delays
- Reviewing data regarding safety, efficacy, and mechanisms of action for available and emerging treatments
- Determining optimal treatment selection and sequencing based on current guidelines and available evidence
- Optimizing transition of care from pediatric to adult management
- Facilitating multidisciplinary team collaboration and care coordination in the management of patients with EoE
- Examining potential impacts of treatment modalities on healthcare costs and utilization, with consideration of economic impact on patients
- Improving recognition and diagnosis of SBS-IF
- Reviewing data regarding safety, efficacy, and mechanisms of action for available and emerging treatments
- Determining optimal management strategies throughout phases of SBS-IF and implementing those strategies in the community care setting
- Optimizing transition of care from pediatric to adult management
- Irritable Bowel Syndrome (IBS)
- Chronic Idiopathic Constipation (CIC)
- Crohn’s Perianal Fistulas (CPF)
Hematology
- Understanding the burden, pathophysiology and the challenges in accurately diagnosing cTTP early
- Exploring testing and monitoring considerations for cTTP
- Evaluating the current standard of care and identifying areas for improvement in medical management
- Reviewing the latest clinical evidence for current and emerging cTTP therapies, their potential benefits and risks, and the importance of disease monitoring
- Outlining prophylactic management strategies for cTTP to prevent sub-acute manifestations and long-term organ damage
- Evaluating the clinical and/or real-world data of hemophilia A therapies and their potential to improve outcomes
- Differentiating current and emerging treatment options, including physiological roles of treatments beyond coagulation
- Personalizing dose and frequency of treatment, including pharmacokinetic-guided dosing
- Addressing the challenges of treating hemophilia A alongside other comorbidities or scenarios including, but not limited to, physical activity, surgery or eradicating factor VIII inhibitors
- Addressing unmet needs of women with hemophilia including importance of early diagnosis and appropriate treatment options
- Understanding the importance of multimeric profile in the treatment of VWD
- Clinical impact of replacement therapy with VWF interaction with endogenous FVIII levels.
- Addressing the consequences of inadequate or suboptimal care
- Impact of prophylaxis in the VWD population
- Treating according to clinical severity
- Reviewing the existing therapeutic approaches available for VWD management including benefits and limitations
- Identifying the challenges faced in the treatment of VWD, exploring innovative strategies for improved patient care through tailored treatment plans, ideal ways to monitor patients in clinical practice.
Immunology
- Reinforce timely screening, diagnosis, and referral for patients at risk for or suspected of having AATD, including those with COPD and asthma, per guidelines
- Recognize the value of early treatment, adherence to treatment, monitoring, and care of patients with AATD
- Raise awareness of the disease burden of AATD, current standard of care, guidelines, and treatment goals
- Adopt shared decision-making between patients and their multidisciplinary care team, supporting patient knowledge of treatment options, and encouraging adherence to therapy to preserve lung function
- Highlighting the CIDP patient journey including burden of illness, diagnostic delay and guideline approaches for differential diagnosis
- Enhancing understanding of treatment guidelines for induction and maintenance treatment of CIDP
- Evaluating safety, efficacy, and administration of treatment options for patients with CIDP
- Addressing health equity and healthcare disparities in the neuromuscular disease community
- Reinforcing long-term efficacy and safety for reducing HAE burden of disease
- Improving recognition of the clinical presentation and diagnostic criteria
- Exploring the importance of tailoring care in adult and pediatric patients, including treatment and prophylaxis
- Assessing the impact of HAE on quality of life and exploring strategies to improve it
- Examining social determinants of health (SDOH) faced by patients with HAE and the impact on disease management and outcomes
- Understanding the unique challenges faced by patients living in rural areas and effective strategies to manage HAE in these populations
Neuromuscular disorders other than CIDP
Neuroscience
- Raising awareness of cerebral cholesterol pathway in epilepsy
- Reviewing data regarding safety, efficacy, and mechanisms of action of emerging treatments for drug-resistant epilepsies such as DEEs
- Narcolepsy or sleep disorders
- Attention-deficit/hyperactivity disorder (ADHD)
- Parkinson Disease
- Huntington Disease
- Alzheimer Disease
Rare Metabolic Diseases
- Emphasizing the importance of newborn screening initiatives and biomarkers to enable early diagnosis
- Evaluating the safety and efficacy of available treatments
- Addressing challenges in Women’s Health in Gaucher Disease and strategies to support personalized care
- Identifying the challenges faced by patients with Gaucher Disease and their caregivers
- Improving patient outcomes through newborn screening (NBS) and strategies to support implementation of NBS
- Optimizing disease management strategies to support personalized care for individuals
- Identifying the challenges faced by patients with Hunter Syndrome and their caregivers
- Metachromatic Leukodystrophy (MLD)
- Fabry Disease
- Adrenal Insufficiency
- Complications of Prematurity
- Dystrophic Epidermolysis Bullosa
- Neonatal Complications
- Stem Cell Transplant
Transplant
- Understanding the burden of illness and unmet needs of inadequately treated CMVi among transplant recipients
- Identifying risk factors and mitigation strategies for CMVi reactivation and inadequately treated CMVi
- Highlighting the importance of early identification and monitoring of hig-risk post-transplant patients for timeline treatment intervention/s
- Addressing challenges in managing tolerability or adverse effects of anti-viral treatments for CMVi
- Identifying barriers and unmet treatment needs for post-transplant recipients with CMVi, including treatment intolerance and inadequately treated, refractory or drug-resistant CMVi
- Evaluating safety, efficacy and impact of modern treatment strategies for CMVi
Vaccines
- Dengue
Dermatology
- Psoriasis and Psoriatic Arthritis
Please visit Takeda Support for additional information on submitting medical education grant requests.
If you have any questions regarding Takeda’s medical education grants, please contact [email protected].